Imetelstat - Janssen Biotech

Drug Profile

Imetelstat - Janssen Biotech

Alternative Names: GRN 140719; GRN 163; GRN 163-L; GRN 719; GRN163L peptide; Imetelstat sodium; JNJ-63935937

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Geron Corporation
  • Developer Geron Corporation; Janssen Biotech
  • Class Antineoplastics; Oligonucleotides; Oligopeptides
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Myelodysplastic syndromes
  • Phase II Myelofibrosis
  • Preclinical Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Suspended Multiple myeloma
  • Discontinued Breast cancer; Essential thrombocythaemia; Lymphoproliferative disorders; Non-small cell lung cancer; Polycythaemia vera; Solid tumours

Most Recent Events

  • 19 Mar 2018 Janssen completes enrolment in a phase-II clinical trial for Myelofibrosis in USA, United Kingdom, Belgium, France, Germany, Spain, Taiwan, Canada, Israel, South Korea and Switzerland
  • 23 Jan 2018 Janssen Biotech announces intention to submit regulatory applications in USA and European Union for Myelofibrosis between 2018 - 2021 (Johnson & Johnson pipeline, February 2018)
  • 20 Dec 2017 Pharmacodynamics data in Myelofibrosis, Chronic myeloid leukaemia and Acute myeloid leukaemia presented at the the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top